Le document « Directives nationales pour la prise en charge du paludisme en RDC », publié en 2023 par le PNLP et le Ministère de la Santé, définit les protocoles officiels pour diagnostiquer et traiter le paludisme sur l’ensemble du territoire. Il recommande l’usage systématique du te...st de diagnostic rapide avant tout traitement, et l’administration des CTA pour le paludisme simple et de l’artésunate injectable pour les cas graves. Le texte insiste sur la gratuité des soins pour les enfants de moins de 5 ans et les femmes enceintes, la gestion rationnelle des médicaments et la formation continue du personnel de santé. Ces directives visent à réduire la mortalité et à atteindre l’élimination du paludisme d’ici 2030.
more
La deuxième édition de ce manuel fournit des directives simples, concrètes et faciles à suivre pour la récupération et le stockage des corps des personnes décédées lors de catastrophes et l’enregistrement des informations les concernant, l’objectif étant d’aider les premiers interven...ants à faire en sorte que les morts soient traités avec respect et que les informations indispensables pour leur identification ultérieure soient enregistrées comme il se doit. Cette version révisée et actualisée de l’ouvrage incorpore l’expérience acquise lors de catastrophes récentes, comme le typhon Haiyan qui a touché les Philippines en 2013, l’épidémie d’Ebola qui s’est déclarée en Afrique de l’Ouest en 2014 et 2015, et le tremblement de terre qui a frappé le Népal en 2015. Elle comporte également plusieurs annexes traitant de diverses questions, telles que la prise en charge des dépouilles des victimes d’une épidémie de maladie infectieuse, la planification des sites d’inhumation et l’utilisation des analyses ADN lors de catastrophes de grande ampleur.
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
A Global Inventory of Alternative Medical Waste Treatment Technologies
La atención concedida a la equidad en la Agenda 2030 para el Desarrollo Sostenible obliga a encontrar nuevas formas de ampliar progresivamente los servicios a las poblaciones que no los reciben. Las alianzas satisfactorias entre el sector encargado del suministro de agua, el saneamiento y la higien...e (WASH, por su sigla en inglés) y los programas de lucha contra las enfermedades tropicales desatendidas (ETD) pueden contribuir a lograr esta aspiración. Sin embargo, colaborar para encontrar juntos esas nuevas formas, exige nuevos modos de pensar. En esta edición corregida se presenta un conjunto de herramientas para ayudar a los países y los programas de lucha contra la ETD a colaborar con la comunidad relacionada con las acciones de agua, saneamiento e higiene, y guía en la creación de alianzas, en la movilización de recursos y en el diseño, la aplicación y la evaluación de las intervenciones. Más que una guía de “buenas prácticas”, se trata de un conjunto de herramientas basadas en la experiencia adquirida en la realidad de un programa.
more
Over the past few decades and throughout the world, the landscape of adolescent health has been altered dramatically. Currently, the total population of adolescents between the ages of 10 and 19 years is 1.2 billion – the largest generation of young people in history. The vast majority of adolesce...nts (85%) live in developing countries where, in many areas, they make up more than a third of the population. They face a variety of different experiences given the diverse political, economic, social and cultural realities within their communities. Although, for many, adolescence is a period of learning and building confidence in a nurturing environment, for others it is a period of heightened risk and complex challenges.
more
Adolescence is a critical stage in life for physical, cognitive and emotional development, shaping future health and well-being. Comprehensive measurement of adolescent health is essential to prioritize health issues, guide interventions and track progress. However, global, regional and national ado...lescent health measurement has historically been inconsistent and incomplete.
more
Guidelines for District Health Managers
La concentration en éthanol est mesurée par une méthode densitométrique à l’aide d’un alcoomètre Gay LUSSAC à l’échelle v/v.
Le présent guide a été conçu comme un outil simple et pratique pour aider les administrateurs sanitaires des districts à élaborer un plan réaliste à leur niveau, afin de mieux gérer l'élimination des déchets produits par les injectio